Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation

Hepatology

Volumn 59, Issue 1, 2014, Pages 35-45

  Nagai, Shunji ^a   Yoshida, Atsushi ^a   Kohno, Keisuke ^a,b   Altshuler, David ^a   Nakamura, Mio ^a   Brown, Kimberly A ^a   Abouljoud, Marwan S ^a   Moonka, Dilip ^a  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; FEMALE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; VIRUS LOAD; ANIMAL; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; LIVER CIRRHOSIS; MORTALITY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; RABBIT; RETROSPECTIVE STUDY; UNITED STATES; DRUG EFFECT; POSTOPERATIVE COMPLICATION;

ANIMALS; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MICHIGAN; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; RABBITS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 84894814333     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26536     Document Type: Article

References (35)

1. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373-1383.e1371.
2. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005;11:434-440.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-34.
4. Alonso O, Loinaz C, Moreno E, Jiménez C, Abradelo M, Gómez R, et al. Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl Int 2005;18:902-907.
5. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005;5:549-557.
6. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
7. Berenguer M, Prieto M, Córdoba J, Rayón JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756-763.
8. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
9. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 2011;60:268-278.
10. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008;14:31-40.
11. Alkhouri N, Hanouneh IA, Lopez R, Zein NN. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression. Liver Transpl 2010;16:155-162.
12. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011;98:268-274.
13. Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501.
14. Shoukry NH, Pelletier S, Chang KM. A view to natural killer cells in hepatitis C. Gastroenterology 2011;141:1144-1148.
15. Kornberg A, Küpper B, Tannapfel A, Thrum K, Bärthel E, Settmacher U. Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology. Liver Int 2006;26:811-816.
16. Bharat A, Barros F, Narayanan K, Borg B, Lisker-Melman M, Shenoy S, et al. Characterization of virus-specific T-cell immunity in liver allograft recipients with HCV-induced cirrhosis. Am J Transplant 2008;8:1214-1220.
17. Romo EM, Muñoz-Robles JA, Castillo-Rama M, Meneu JC, Moreno-Elola A, Pérez-Saborido B, et al. Peripheral blood lymphocyte populations in end-stage liver diseases. J Clin Gastroenterol 2007;41:713-721.
18. Rasmussen AL, Tchitchek N, Susnow NJ, Krasnoselsky AL, Diamond DL, Yeh MM, et al. Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients. Hepatology 2012;56:17-27.
19. de Jager CP, van Wijk PT, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care 2010;14:R192.
20. Heffernan DS, Monaghan SF, Thakkar RK, Machan JT, Cioffi WG, Ayala A. Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern. Crit Care 2012;16:R12.
21. Martí J, Armadans L, Vaqué J, Segura F, Schwartz S. [Protein-calorie malnutrition and lymphocytopenia as predictors of hospital infection in the elderly.] Med Clin (Barc) 2001;116:446-450.
22. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010;10:590-601.
23. Bogetti D, Jarzembowski TM, Sankary HN, Manzelli A, Knight PS, Chejfec G, et al. Hepatic ischemia/reperfusion injury can be modulated with thymoglobulin induction therapy. Transpl Proc 2005;37:404-406.
24. Beiras-Fernandez A, Chappell D, Hammer C, Beiras A, Reichart B, Thein E. Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transpl Immunol 2009;20:224-228.
25. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000;6:407-412.
26. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006;12:134-139.
27. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-474.
28. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002;73:1514-1518.
29. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-687.
30. Beier-Holgersen R, Brandstrup B. Influence of postoperative enteral nutrition on cellular immunity. A random double-blinded placebo controlled clinical trial. Int J Colorectal Dis 2012;27:513-520.
31. Cereda E, Pusani C, Limonta D, Vanotti A. The association of Geriatric Nutritional Risk Index and total lymphocyte count with short-term nutrition-related complications in institutionalised elderly. J Am Coll Nutr 2008;27:406-413.
32. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, Ezaki T. Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today 2010;40:440-443.
33. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-29.
34. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011;17:1394-1403.
35. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012;56:973-983.